DP
Therapeutic Areas
Ocular Therapeutix Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AXPAXLI (OTX-TKI) | Wet Age-Related Macular Degeneration | NDA Submitted |
| OTX-CSI | Chronic Dry Eye Disease | Phase 3 |
| OTX-TIC | Glaucoma / Ocular Hypertension | Phase 1 |
| DEXTENZA | Post-Surgical Inflammation/Pain; Allergic Conjunctivitis | Marketed |
Leadership Team at Ocular Therapeutix
AM
Antony Mattessich
President and Chief Executive Officer
DN
Donald Notman
Chief Financial Officer
DR
Dr. Rabia Gurses-Ozden, MD
Chief Medical Officer
DM
Dr. Michael Goldstein, MD, MBA
President, Ophthalmology
JC
John Corbet
Chief Commercial Officer